重组人B7-H1IgV疫苗对小鼠骨髓瘤细胞的抑制作用  

Inhibitory effect of rhB7-H1IgV protein vaccination on SP2/0 tumor cells

作　　者：陈霖[1] 王伟华[1] 张存[1] 薛晓畅[1] 李萌[1] 李维娜[1] 韩苇[1] 颜真[2] 张英起[1] 

机构地区：[1]第四军医大学药学系生物技术中心,陕西西安710033 [2]第四军医大学药学系药物基因组学教研室,陕西西安710033

出　　处：《第四军医大学学报》2007年第21期1970-1972,共3页Journal of the Fourth Military Medical University

摘　　要：目的:探讨重组人B7-H1IgV融合蛋白对小鼠骨髓瘤的预防和治疗效果及其对荷瘤小鼠外周血中CD4+CD25+T细胞水平的影响.方法:用重组人B7-H1IgV融合蛋白免疫小鼠,待抗体产生后接种SP2/0肿瘤细胞作为预防组;用重组人B7-H1IgV融合蛋白免疫小鼠,同时接种SP2/0肿瘤细胞作为治疗组.监测小鼠体质量、肿瘤体积的变化及生存期;检测小鼠体内CD4+CD25+T细胞水平.结果:重组人B7-H1IgV融合蛋白在预防组和治疗组中均显示出了较好的抑瘤作用,并可显著降低治疗组小鼠体内CD4+CD25+T细胞水平.结论:重组人B7-H1IgV融合蛋白能够引起小鼠的体液免疫,并抑制SP2/0肿瘤细胞的生长,从而延长荷瘤小鼠的生存期.rhB7-H1IgV融合蛋白肿瘤疫苗有望成为一种肿瘤免疫治疗的候选者.AIM： To analyze the preventive and therapeutic effects of recombinant human B7-HIIgV fusion protein on SP2/0 tumor-bearing mice and observe the change of CD4^＋ CD25^＋ T cell number in mice. METHODS ： The mice of prevention group were inoculated subcutaneously with SP2/0 tumor cells after immunized with rhB7-HllgV protein. The mice of treatment group were inoculated with SP2/0 tumor cells and immunized with rhB7-HllgV protein at the same time. Then we observed the body weight, tumor growth, survival time and the level of CD4^＋ CD25^＋ T cells in mice. RESULTS ： rhB7-H11gV protein delayed tumor growth, prolonged the survival time and decreased the level of CD4^＋ CD25^＋ T cells in SP2/0 tumor-bearing mice, CONCLUSION： B7-HIIgV fusion protein can activate humoral immune response in mice. It can not only inhibit the tumor growth, but also prolong the survival time of SP2/0 tumor-bearing mice. The rhB7-HllgV fusion protein might be used to develop a new autovaccine in tumor immunotherapy.

关 键 词：小鼠骨髓瘤细胞 肿瘤疫苗 重组 抑制作用 SP2/0 融合蛋白 细胞水平 肿瘤细胞 

分 类 号：R392-33[医药卫生—免疫学]